Granules India Limited (BOM:532482)
India · Delayed Price · Currency is INR | Market Cap | 204.61B +48.1% |
| Revenue (ttm) | 56.32B +24.8% |
| Net Income | 6.62B +38.1% |
| EPS | 26.95 +36.3% |
| Shares Out | 247.80M |
| PE Ratio | 30.64 |
| Forward PE | 24.94 |
| Dividend | 1.75 (0.21%) |
| Ex-Dividend Date | Jul 30, 2026 |
| Volume | 27,108 |
| Open | 814.15 |
| Previous Close | 812.95 |
| Day's Range | 801.95 - 833.35 |
| 52-Week Range | 520.05 - 922.10 |
| Beta | 0.12 |
| Analysts | Buy |
| Price Target | 907.25 (+9.88%) |
| Est. Earnings | Oct 23, 2026 |
About Granules India
Granules India Limited manufactures and sells active pharmaceutical ingredients (APIs), pharmaceutical formulation intermediates (PFIs), finished dosages (FDs), and peptides CDMO in India and internationally. It offers paracetamol, metformin, guaifenesin, ibuprofen, and methocarbamol, as well as prescription and over-the-counter products. The company also develops and manufactures tablets, capsules, press fits, oral solutions, suspensions, and powder for oral solutions. In addition, it provides development and manufacturing solutions for peptid... [Read more]
Financial Performance
In fiscal year 2026, Granules India's revenue was 53.66 billion, an increase of 19.73% compared to the previous year's 44.82 billion. Earnings were 5.95 billion, an increase of 18.64%.
Financial StatementsAnalyst Summary
According to 8 analysts, the average rating for 532482 stock is "Buy." The 12-month stock price target is ₹907.25, which is an increase of 9.88% from the latest price.
News
Granules India plans ₹2,000 crore investment to drive growth in complex generics, oncology, and peptide CDMO
Granules India plans ₹2,000 crore capex over 3-4 years to expand complex generics, oncology and peptide CDMO, boosting US and global growth.
Hyderabad Granules promoter sells 7% stake to raise 1.5k crore
Krishna Prasad Chigurupati sold a significant stake in Granules India on Friday. This stake sale raised over 1,160 crore through numerous block deals. The funds will support the drugmaker's ongoing gr...
Granules India Transcript: Q1 26/27
Q1 FY 2027 saw 22% revenue growth, margin expansion, and strong cash flow, led by complex generics and peptide CDMO. Regulatory remediation is nearly complete, with multiple launches pending FDA clearance and robust growth expected across segments.
Granules India Quarterly report: Q1 2027
Granules India has published its Q1 2027 quarterly earnings report on July 21, 2026.
Granules India Slides: Q1 2027
Granules India has posted slides in relation to its Q1 2027 quarterly earnings report, which was published on July 21, 2026.
Granules India's first-quarter profit surges as margins improve
Drugmaker Granules India reported a nearly 60% rise in first-quarter profit on Tuesday as margins improved in its complex generics business.
Granules India secures sole First-to-File status for generic drug
Granules India wins FDA sole first-to-file status for sodium oxybate extended-release ANDA, a generic of Alkermes’ LUMRYZ, with potential 180-day exclusivity.
Granules India shares gain 2% after company secures Sole First-to-File status for Sodium Oxybate ANDA in US
Granules India shares gained around 2% in early trade after the company announced that it has secured Sole First-to-File (FTF) status for its Abbreviated New Drug Application (ANDA) for Sodium…
Granules India secures sole first-to-file ANDA status for sodium oxybate
Granules India Limited has achieved Sole First-to-File (FTF) status for its Abbreviated New Drug Application (ANDA) for Sodium Oxybate Extended-Release for Oral Suspension, marking a significant miles...
Granules India subsidiary receives USFDA EIR for Chantilly facility
Granules India Limited has announced that its wholly-owned subsidiary, Granules Pharmaceuticals, Inc. (GPI), located in Chantilly, Virginia, US, has received the Establishment Inspection Report (EIR) ...
Why are Granules India shares up nearly 5% today? Block deal worth 15.3 lakh shares triggers buying interest
Shares of Granules India gained nearly 5% on Wednesday after a large block deal involving approximately 15.3 lakh shares was executed on the exchanges, boosting investor interest in the pharmaceutical...
Granules India Transcript: Q4 25/26
FY 2026 saw strong revenue and margin growth, driven by complex generics, CDMO expansion, and operational improvements. Regulatory remediation progressed, with Gagillapur audit readiness and lower remediation costs expected in FY 2027. CapEx will focus on API, IT, and distribution.
Granules India Quarterly report: Q4 2026
Granules India has published its Q4 2026 quarterly earnings report on April 29, 2026.
Granules India Slides: Q4 2026
Granules India has posted slides in relation to its Q4 2026 quarterly earnings report, which was published on April 29, 2026.
Granules India Annual report: Q4 2026
Granules India has published its Q4 2026 annual report on April 29, 2026.
Granules India reports 23% YoY revenue growth in Q4FY26
Granules India Ltd., a vertically integrated pharmaceutical company, announced a robust financial performance for the quarter and financial year ended March 31, 2026. The company reported a 23% year-o...
Granules India completes cGMP audit at Chantilly site with four FDA observations
Granules India Limited has announced the completion of a routine current Good Manufacturing Practices (cGMP) audit by the US Food and Drug Administration (FDA) at its Chantilly, Virginia site. The…
Granules India subsidiary receives VAI classification after US FDA inspection
Granules India Limited announced that its wholly owned subsidiary, Granules Life Sciences Private Limited (GLS), has successfully concluded a US FDA inspection with a Voluntary Action Indicated (VAI) ...
Top stocks to buy today: Stock recommendations for March 27, 2026 - check list
Stock market recommendations: Granules India, and RBL Bank are the top two stocks that Bajaj Broking Research has recommended for March 27, 2026. Views on Nifty, and Bank Nifty have also been shared:
Pharma sector stocks today, March 13: Laurus Labs down 2.56%, Ajanta Pharma falls 1.88%, Granules India drops 2.14%
The Indian pharmaceutical sector showed a downward trend in early trading on March 13, 2026, aligning with broader market weakness. The S&P BSE Healthcare Index stood at 43,441.0, down 0.6%…
Pharma sector stocks surge today, March 10: Natco Pharma up 4%, Granules India jumps 3.31%, Glenmark Pharma rises 2.72%
The pharmaceutical sector in India showed positive movement on March 10, 2026, during early trading hours, with many stocks recording gains as of approximately 9:36 AM IST on BSE and…
Granules India subsidiary receives US FDA EIR with NAI status for Virginia facility
Granules India Limited announced that its US step-down subsidiary, Granules Consumer Health, LLC, has received an Establishment Inspection Report (EIR) with a No Action Indicated (NAI) status from the...
Pharma sector stocks surge today, March 5: Natco Pharma jumps 3.35%, Granules India up 2.74%, Alembic surge nearly 2%
Pharmaceutical stocks in India showed mixed performance on March 5, 2026, during early trading hours, with many recording modest gains amid broader market movements. The S&P BSE HEALTHCARE Index stood...
Granules India shares jump over 4% as Q3 net profit up 28% YoY
Shares of Granules India were trading over 4% higher on Tuesday, January 27, after the pharmaceutical major reported a strong...
Granules India Transcript: Q3 25/26
Q3 FY26 saw 22% revenue and 34% EBITDA growth, with margin expansion and strong performance in complex generics and peptide CDMO. Regulatory progress, capacity expansion, and new launches are set to drive further growth, despite ongoing FDA remediation at Gagillapur.